scout
Opinion|Videos|January 24, 2024

REACH3: Ruxolitinib in Steroid Refractory cGvHD

Dr. Zeiser discusses the recent data presented at ASH 2023 of the REACH3 trial.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME